Drug Profile
GSK 1674330A
Alternative Names: GSK-1674330A; HPV-16/18/33/58 tetravalent vaccine; Human papillomavirus (types 16, 18, 33, 58) L1 virus-like particle vaccine - GSK; Human papillomavirus (types 16, 18, 33, 58) L1 VLP vaccine - GSK; Human papillomavirus quadrivalent (types 16, 18, 33, 58) recombinant vaccine - GSK; Tetravalent HPV L1 16/18/33/58 virus-like particle vaccine - GSKLatest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cervical cancer; Human papillomavirus infections
Most Recent Events
- 24 Mar 2014 Final efficacy and adverse events data from a phase I/II trial in Human papillomavirus infections (prevention) published in Vaccine
- 01 Feb 2014 Discontinued - Phase-I for Human papillomavirus infections in Belgium (IM)
- 01 Feb 2014 Discontinued - Phase-I/II for Cervical cancer in Belgium (IM)